Induced Pluripotent Stem Cell (iPS Cell) Market - 2024-2033

June 2025 | 210 pages | ID: I8CA48B3EB34EN
DataM Intelligence

Abstracts

The Induced Pluripotent Stem Cell (iPS Cell) Market was valued at US$ 1.98 Billion in 2024 and is anticipated to reach US$ 4.66 Billion by 2033, at a CAGR of 0.101 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Induced Pluripotent Stem Cell (iPS Cell) Market.

This report delivers a comprehensive overview of the Induced Pluripotent Stem Cell (iPS Cell) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Induced Pluripotent Stem Cell (iPS Cell) Market. The Induced Pluripotent Stem Cell (iPS Cell) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Induced Pluripotent Stem Cell (iPS Cell) Market Scope:

Key Players

• Thermo Fisher Scientific Inc.

Major Highlights

This report delivers a comprehensive overview of the Induced Pluripotent Stem Cell (iPS Cell) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Induced Pluripotent Stem Cell (iPS Cell) Market. The Induced Pluripotent Stem Cell (iPS Cell) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

3.1. Key Trends and Future Projections
3.2. Snippet by Product Type
3.3. Snippet by Application
3.4. Snippet by Disease Area
3.5. Snippet by End-User
3.6. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Increased Application in Disease Modeling and Drug Screening
    4.1.1.2. Strong Pipeline of iPSC
    4.1.1.3. Rising Incidence of Chronic and Genetic Diseases
  4.1.2. Restraints
    4.1.2.1. Safety Concerns Related to Genetic and Epigenetic Instability
    4.1.2.2. Slow Regulatory Approval Process
    4.1.2.3. Competition from Alternative Technologies
  4.1.3. Opportunity
    4.1.3.1. Personalized Medicine and Patient-Specific Therapies
    4.1.3.2. Expansion in Rare and Genetic Diseases
    4.1.3.3. Emergence of Cell-Based Regenerative Therapies
  4.1.4. Impact Analysis

5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

5.1. Market Leaders and Pioneers
  5.1.1. Emerging Pioneers and Prominent Players
  5.1.2. Established Leaders with the Largest Marketing Brand
  5.1.3. Market Leaders with Established Products
5.2. Latest Developments and Breakthroughs
5.3. Regulatory and Reimbursement Landscape
  5.3.1. North America
  5.3.2. Europe
  5.3.3. Asia Pacific
  5.3.4. South America
  5.3.5. Middle East & Africa
5.4. Porter’s Five Forces Analysis
5.5. Supply Chain Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. Unmet Needs and Gaps
5.9. Recommended Strategies for Market Entry and Expansion
5.10. Pricing Analysis and Price Dynamics

6. INDUCED PLURIPOTENT STEM CELL (IPS CELL) MARKET, BY PRODUCT TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  6.1.2. Market Attractiveness Index, By Product Type
6.2. Cell Lines*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  6.2.3. Human iPSC Lines
  6.2.4. Mouse iPSC Lines
6.3. iPSC-Derived Cells
  6.3.1. iPSC-derived Neurons
  6.3.2. iPSC-derived Cardiomyocytes
  6.3.3. iPSC-derived Hematopoietic Cells
  6.3.4. Others
6.4. Reprogramming Products
  6.4.1. Vectors
  6.4.2. Culture Media
  6.4.3. Others

7. INDUCED PLURIPOTENT STEM CELL (IPS CELL) MARKET, BY APPLICATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  7.1.2. Market Attractiveness Index, By Application
7.2. Drug Development and Toxicology Screening*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Disease Modeling
7.4. Regenerative Medicine and Cell Therapy
7.5. Academic Research
7.6. Stem Cell Banking
7.7. Gene Therapy
7.8. Others

8. INDUCED PLURIPOTENT STEM CELL (IPS CELL) MARKET, BY DISEASE AREA

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  8.1.2. Market Attractiveness Index, By Disease Area
8.2. Neurological Disorders*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular Diseases
8.4. Hematological Diseases
8.5. Metabolic Disorders
8.6. Infectious Diseases
8.7. Oncology
8.8. Rare Diseases
8.9. Others

9. INDUCED PLURIPOTENT STEM CELL (IPS CELL) MARKET, BY END-USER

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  9.1.2. Market Attractiveness Index, By End-User
9.2. Academic and Research Institutes*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pharmaceutical and Biotechnology Companies
9.4. Hospitals and Clinics
9.5. Contract Research Organizations (CROs)
9.6. Stem Cell Banks
9.7. Others

10. INDUCED PLURIPOTENT STEM CELL (IPS CELL) MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

11. INTRODUCTION

11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.1. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.7.1. U.S.
    11.2.7.2. Canada
    11.2.7.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.7.1. Germany
    11.3.7.2. UK
    11.3.7.3. France
    11.3.7.4. Spain
    11.3.7.5. Italy
    11.3.7.6. Rest of Europe
11.4. Asia-Pacific
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. China
    11.4.7.2. India
    11.4.7.3. Japan
    11.4.7.4. South Korea
    11.4.7.5. Rest of Asia-Pacific
11.5. South America
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. Brazil
    11.5.7.2. Argentina
    11.5.7.3. Rest of South America
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

13. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS

13.1. Market Share Analysis and Positioning Matrix
13.2. Strategic Partnerships, Mergers & Acquisitions
13.3. Key Developments in Product Portfolios and Innovations
13.4. Company Benchmarking

14. COMPANY PROFILES

14.1. Thermo Fisher Scientific Inc.*
  14.1.1. Company Overview
  14.1.2. Product Portfolio
    14.1.2.1. Product Description
    14.1.2.2. Product Key Performance Indicators (KPIs)

15. FINANCIAL OVERVIEW

15.1. Company Revenue
  15.1.1. Geographical Revenue Shares
    15.1.1.1. Revenue Forecasts
  15.1.2. Key Developments
    15.1.2.1. Mergers & Acquisitions
    15.1.2.2. Key Product Development Activities
    15.1.2.3. Regulatory Approvals, etc.
  15.1.3. SWOT Analysis
15.2. REPROCELL Inc.
15.3. FUJIFILM Cellular Dynamics
15.4. Axol Bioscience Ltd.
15.5. Evotec
15.6. Takara Bio Inc.
15.7. Fate Therapeutics
15.8. BlueRock Therapeutics LP
15.9. Aspen Neuroscience
15.10. Ncardia( LIST NOT EXHAUSTIVE)

16. ASSUMPTIONS AND RESEARCH METHODOLOGY

16.1. Data Collection Methods
16.2. Data Triangulation
16.3. Forecasting Techniques
16.4. Data Verification and Validation

17. APPENDIX

17.1. About Us and Services
17.2. Contact Us